Showing 2331-2340 of 5771 results for "".
- Foundation Fighting Blindness to Host Annual Retinal Cell & Gene Therapy Innovation Summit Before ARVOhttps://modernod.com/news/foundation-fighting-blindness-to-host-annual-retinal-cell-gene-therapy-innovation-summit-before-arvo/2476488/The Foundation Fighting Blindness will co-host the 6th annual Retinal Cell and Gene Therapy Innovation Summit, in partnership with the Casey Eye Institute at Oregon Health & Science University. The summit–one of the world’s most comprehensive reviews (three dozen presenters) of ongoing
- Clearside Biomedical Announces Presentations on its Suprachoroidal Space Injection Platform at Upcoming Medical Meetingshttps://modernod.com/news/clearside-biomedical-announces-presentations-on-its-suprachoroidal-space-injection-platform-at-upcoming-medical-meetings/2476477/Clearside Biomedical announced that multiple presentations will be made on Clearside’s Suprachoroidal Space (SCS) injection platform at upcoming ophthalmology and gene therapy medical meetings in Vancouver, British Columbia. The presentations will highlight the benefits of the company’s SCS injec
- Innovent Announces First Patient Dosed in a Phase 1 Clinical Trial of IBI302 for the Treatment of Wet AMDhttps://modernod.com/news/innovent-announces-first-patient-dosed-in-a-phase-1-clinical-trial-of-ibi302-for-the-treatment-of-wet-amd/2476478/Innovent Biologics announced that the first patient has been successfully dosed in a phase 1 clinical trial of IBI302, a novel recombinant fully human bispecific fusion protein targeting both vascular endothelium growth factor (VEGF) and complement proteins, for the treatment of wet age-related m
- Novartis Announces FDA BLA Acceptance of Brolucizumab for Wet AMDhttps://modernod.com/news/novartis-announces-fda-filing-acceptance-and-priority-review-of-brolucizumab-for-wet-amd/2476468/Novartis announced that the FDA has accepted the company’s biologics license application (BLA) for brolucizumab (RTH258) for the treatment of wet age-related macular degeneration (AMD). Novartis used a priority review voucher to expedite FDA review and anticipates launching brolucizumab, if
- NovaBay Pharmaceuticals Announces New Partner Pharmacy Programhttps://modernod.com/news/novabay-pharmaceuticals-announces-new-partner-pharmacy-program/2476465/NovaBay Pharmaceuticals announced a new pharmacy partnering program in an effort to ensure all patients in the United States have reliable and affordable access to prescription Avenova, according to a company news release. NovaBay has recently added six new pharmacies as Avenova channel partners.
- Oxurion NV Announces Full Enrollment of Its Phase 2 Trial Evaluating Combination of Anti-PlGF (THR-317) and Anti-VEGF (Ranibizumab) for the Treatment of DMEhttps://modernod.com/news/oxurion-nv-announces-full-enrollment-of-its-phase-2-trial-evaluating-combination-of-anti-plgf-thr-317-and-anti-vegf-ranibizumab-for-the-treatment-of-dme/2476439/Oxurion NV announced that all patients have been enrolled in its phase 2 trial evaluating its THR-317, a humanized antibody against placental growth factor (PlGF), in combination with anti-VEGF (ranibizumab), an anti-vascular endothelial growth factor (VEGF) antibody, for the treatment of diabeti
- ARVO Foundation Announces New Mallinckrodt Uveitis Research Fellowshiphttps://modernod.com/news/arvo-foundation-announces-new-mallinckrodt-uveitis-research-fellowship/2476437/The Association for Research in Vision and Ophthalmology (ARVO) announced the launch of a new fellowship for early-career researchers. The Ma
- Alcon Announces Timothy Stonesifer as Chief Financial Officerhttps://modernod.com/news/alcon-announces-timothy-stonesifer-as-chief-financial-officer/2476432/Alcon announced that Timothy C. Stonesifer will join the company as its new Senior Vice President and Chief Financial Officer, in conjunction with the company’s April 9 spinoff from Novartis. He will report directly to David Endicott, Alcon’s Chief Executive Officer, and bec
- Bausch + Lomb Announces US Launch of Lotemax SMhttps://modernod.com/news/bausch-lomb-announces-us-launch-of-lotemax-sm-0-38-for-treatment-of-postoperative-inflammation-and-pain/2476431/Bausch + Lomb announced it has launched Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, indicated for the treatment of postoperative inflammation and pain following ocular surgery. The company received final approval by the FDA on February 22, 2019. Lotemax SM is a new gel drop fo
- Ocular Therapeutix Announces Supplemental NDA Accepted by FDA for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-supplemental-nda-accepted-by-fda-for-dextenza/2476429/Ocular Therapeutix announced the FDA has accepted the filing of the supplemental new drug application (sNDA) for Dextenza (dexamethasone ophthalmic insert) to include the treatment of ocular inflammation following ophthalmic surgery in its label. The notice of acceptance confirms the FDA has comp